Clinical Trials Browser

taletrectinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Phase 3 Recruiting

194 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Phase 2 Active not recruiting

217 enrolled 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06841874 2025-12-24

Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT07199010 2025-09-30

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Not yet recruiting

50 enrolled

Thoracic

Non-small Lung Cancer

NCT07008287 2025-07-22

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06214793 2025-05-01

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)

Phase 2 Suspended

61 enrolled

Breast

Breast Neoplasms

Clinical Trials

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

TRUST-II

Tale EAP

Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression

Real-world Study of Taletrectinib for Advanced ROS1+ NSCLC With Brain Metastases

Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC)